Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.

PHASE2TerminatedINTERVENTIONAL

Enrollment

219

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Alzheimer´s Disease

Interventions

DRUG

Lornoxicam

Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.

DRUG

Placebo

Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.